Treatment of treatment-resistant autoimmune blistering skin disorders with rituximab
A.Ø. Jensen
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorB.K. Møller
Department of Clinical Immunology,Skejby Sygehus, Århus UniversityHospital, Denmark
Search for more papers by this authorA. Vangkilde
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorB. Mark
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorE.R. Obitz
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorK. Kragballe
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorL. Iversen
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorA.Ø. Jensen
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorB.K. Møller
Department of Clinical Immunology,Skejby Sygehus, Århus UniversityHospital, Denmark
Search for more papers by this authorA. Vangkilde
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorB. Mark
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorE.R. Obitz
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorK. Kragballe
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorL. Iversen
Department of Dermatology, Århus Sygehus,P. P. Ørumsgade, Århus University Hospital,8000 Århus C, Denmark
Search for more papers by this authorConflicts of interest: none declared.
References
- 1 Agarwal M, Walia R, Kochhar AM, Chander R. Pemphigus Area and Activity Score (PAAS) – a novel clinical scoring method for monitoring of pemphigus vulgaris patients. Int J Dermatol 1998; 37: 158–60.
- 2 Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003; 14: 520–35.
- 3 Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 2003; 28: 366–8.
- 4 Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003; 148: 602–3.
- 5 Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case. Haematologica 2003; 88: ELT24.
- 6 Espana A, Fernandez-Galar M, Lloret P et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004; 50: 974–6.
- 7 Dupuy A, Viguier M, Bedane C et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004; 140: 91–6.
- 8 Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol 2008; 47: 292–4.
- 9 Eming R, Nagel A, Wolff-Franke S et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008; 128: 2850–8.
- 10 Mouquet H, Musette P, Gougeon ML et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008; 128: 2859–69.
